products

G-NiiB CRCcore

Colorectal Cancer Diagnostics

Colorectal cancer (CRC) is one of the most common cancers worldwide. CRC is now the commonest cancer and the second cause of cancer death in Hong Kong. Most CRCs begin as small polyps (adenomas). Early detection of cancer can facilitate successful treatment, and early detection of adenomas can prevent and decrease CRC incidence. Current screening tools such as fecal immunochemical test (FIT) fails to detect adenomas.
To utilise novel microbes to detect cancer early, when it can be cured, and to detect cancer, before it has the chance to develop. Capitalizing on our unique biobank and rapidly expanding metagenome datasets, we have developed a non-invasive disruptive technology for detecting precancer lesion.
Our technology

GenieBiome identifies novel bacterial markers in stool and validates the results based on the our rich metagenome dataset. CRCCORE TM tests are rapid and accurate for early detection of colorectal cancer (sensitivity 94%, specificity 85%) and pre-cancer lesions, adenomas (sensitivity >60%) - it overcomes the physical suffering, inconvenience, high cost and low compliance associated with colonoscopy.


G-NiiB CRCCORE TM has 4 unique value propositions — non-invasive, affordable, sensitive for precancer lesions, and tailored-made with potential for risk monitoring and modulation.

G-NiiB CRCCORE TM is intended to be complementary to international guideline-recommended cancer screening.


Based on survey results from 1,250 respondents from China and South East Asia, majority are willing to use CRCCORE TM ,which is a microbiome-based and non-invasive test, that addresses the unmet needs of people aged 40+. We are supporting our pipelines with clinical trials.

References:
  • Liang JQ , et al. A Novel Fecal Lachnoclostridium Marker for the Non-Invasive Diagnosis of Colorectal Adenoma and Cancer. Gut 2019 Sep 12 DOI 10.1136/gutjnl-2019-318532.

  • Liang JQ , et al. Fecal Bacteria Act as Novel Biomarkers for Non-Invasive Diagnosis of Colorectal Cancer. Clin Cancer Res. 2017 Apr 15;23(8):2061-2070. doi: 10.1158/1078-0432.CCR-16-1599.

  • Yu J, et al. Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017 Jan;66(1):70-78. doi: 10.1136/gutjnl-2015-309800. Epub 2015 Sep 25.

  • Allemani, C., et al., Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018. 391(10125): p. 1023-1075.

  • Sung JJY, Ng SC, Chan FKL, et alAn updated Asia Pacific Consensus Recommendations on colorectal cancer screeningGut 2015;64:121-132.